Which has preferable valuation and earnings, IMVT or AMLX?

Immunovant is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Amylyx Pharmaceuticals N/A N/A -$144.74M -$1.50 N/A

Is IMVT or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Amylyx Pharmaceuticals N/A -55.69% -50.73%

Does the media refer more to IMVT or AMLX?

In the previous week, Immunovant had 10 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for Immunovant and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Immunovant's score of 0.46 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor RYTM or AMLX?

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 3 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Rhythm Pharmaceuticals' score of 1.14 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor MIRM or AMLX?

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Mirum Pharmaceuticals' score of 0.78 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is SYRE or AMLX more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Amylyx Pharmaceuticals N/A -55.69% -50.73%

Does the media favor SYRE or AMLX?

In the previous week, Spyre Therapeutics had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 5 mentions for Spyre Therapeutics and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Spyre Therapeutics' score of 1.03 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer AMLX or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Lantheus' score of 1.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amylyx Pharmaceuticals (AMLX) Competitors

$17.41 -0.36 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$17.40 -0.01 (-0.06%)

As of 06:18 PM Eastern

Compare

AMLX vs. IMVT, RYTM, MIRM, SYRE, and LNTH

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Amylyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amylyx Pharmaceuticals include Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Amylyx Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Immunovant had 10 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for Immunovant and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Immunovant's score of 0.46 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Immunovant presently has a consensus target price of $39.70, indicating a potential upside of 2.58%. Amylyx Pharmaceuticals has a consensus target price of $24.25, indicating a potential upside of 39.29%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amylyx Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Amylyx Pharmaceuticals' return on equity of -55.69% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Immunovant is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Immunovant on 12 of the 14 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	38.82	-$196.54M	-$3.13	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A

Rhythm Pharmaceuticals currently has a consensus target price of $138.29, indicating a potential upside of 28.65%. Amylyx Pharmaceuticals has a consensus target price of $24.25, indicating a potential upside of 39.29%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amylyx Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Rhythm Pharmaceuticals has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 3 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Rhythm Pharmaceuticals' score of 1.14 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Amylyx Pharmaceuticals beats Rhythm Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Mirum Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	12.74	-$23.36M	-$13.61	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Mirum Pharmaceuticals' score of 0.78 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Mirum Pharmaceuticals presently has a consensus price target of $143.40, indicating a potential upside of 20.46%. Amylyx Pharmaceuticals has a consensus price target of $24.25, indicating a potential upside of 39.29%. Given Amylyx Pharmaceuticals' higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Mirum Pharmaceuticals beats Amylyx Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Spyre Therapeutics had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 5 mentions for Spyre Therapeutics and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Spyre Therapeutics' score of 1.03 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Spyre Therapeutics currently has a consensus price target of $101.42, indicating a potential upside of 8.20%. Amylyx Pharmaceuticals has a consensus price target of $24.25, indicating a potential upside of 39.29%. Given Amylyx Pharmaceuticals' higher probable upside, analysts plainly believe Amylyx Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Spyre Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.2, suggesting that its stock price is 120% less volatile than the broader market.

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,261.37	-$155.20M	-$2.08	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A

Spyre Therapeutics' return on equity of -42.88% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Summary

Spyre Therapeutics beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Lantheus?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Lantheus had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Lantheus' score of 1.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A
Lantheus	$1.54B	4.45	$233.56M	$4.15	25.40

Amylyx Pharmaceuticals has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Lantheus	18.05%	29.32%	15.00%

Amylyx Pharmaceuticals presently has a consensus price target of $24.25, suggesting a potential upside of 39.29%. Lantheus has a consensus price target of $108.29, suggesting a potential upside of 2.75%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Amylyx Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lantheus beats Amylyx Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.94B	$2.99B	$6.83B	$12.42B
Dividend Yield	N/A	2.05%	2.68%	8.01%
P/E Ratio	-11.61	19.17	27.15	24.29
Price / Sales	N/A	499.40	524.33	95.60
Price / Cash	N/A	56.80	29.22	49.39
Price / Book	6.26	4.22	10.75	6.29
Net Income	-$144.74M	$64.26M	$3.58B	$330.86M
7 Day Performance	-3.12%	-3.22%	-2.10%	-2.41%
1 Month Performance	19.33%	2.12%	3.32%	-0.64%
1 Year Performance	126.69%	22.04%	28.17%	20.09%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	3.1371 of 5 stars	$17.41 -2.0%	$24.25 +39.3%	+131.4%	$1.94B	N/A	N/A	200	News Coverage Positive News Insider Trade
IMVT Immunovant	2.1401 of 5 stars	$38.60 -0.5%	$39.70 +2.8%	+119.0%	$7.96B	N/A	N/A	120	News Coverage Insider Trade
RYTM Rhythm Pharmaceuticals	3.2754 of 5 stars	$111.68 -2.2%	$136.13 +21.9%	+25.0%	$7.82B	$189.76M	N/A	140
MIRM Mirum Pharmaceuticals	2.5109 of 5 stars	$121.91 -2.9%	$143.00 +17.3%	+131.9%	$7.66B	$521.31M	N/A	140	Positive News
SYRE Spyre Therapeutics	1.8361 of 5 stars	$88.74 +2.4%	$95.83 +8.0%	+522.9%	$7.62B	$890K	N/A	73	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Amylyx Pharmaceuticals compare to Immunovant?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Amylyx Pharmaceuticals compare to Immunovant?

Does the media refer more to IMVT or AMLX?

Do institutionals and insiders believe in IMVT or AMLX?

Do analysts prefer IMVT or AMLX?

Is IMVT or AMLX more profitable?

Which has preferable valuation and earnings, IMVT or AMLX?

Which has more volatility and risk, IMVT or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Do institutionals & insiders hold more shares of RYTM or AMLX?

Is RYTM or AMLX more profitable?

Which has preferable earnings and valuation, RYTM or AMLX?

Do analysts rate RYTM or AMLX?

Which has more volatility and risk, RYTM or AMLX?

Does the media favor RYTM or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Is MIRM or AMLX more profitable?

Which has more risk & volatility, MIRM or AMLX?

Do insiders & institutionals hold more shares of MIRM or AMLX?

Which has better valuation and earnings, MIRM or AMLX?

Does the media favor MIRM or AMLX?

Do analysts recommend MIRM or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Do institutionals and insiders have more ownership in SYRE or AMLX?

Does the media favor SYRE or AMLX?

Do analysts prefer SYRE or AMLX?

Which has more volatility and risk, SYRE or AMLX?

Which has stronger valuation and earnings, SYRE or AMLX?

Is SYRE or AMLX more profitable?

Summary

How does Amylyx Pharmaceuticals compare to Lantheus?

Does the media prefer AMLX or LNTH?

Which has stronger earnings and valuation, AMLX or LNTH?

Which has more volatility & risk, AMLX or LNTH?

Is AMLX or LNTH more profitable?

Do analysts prefer AMLX or LNTH?

Do insiders & institutionals have more ownership in AMLX or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools